Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00448357 · OUTCOME

Incidence of DNA Chimerism in Patients Between One Month Post Transplant

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen · Source last updated 2017-07-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
30 days post transplant

What was measured

Deoxyribonucleic acid (DNA) chimerism is a measure identifying the genetic profiles of the transplant recipient and of the donor and then evaluating the extent of mixture in the recipient's blood, bone marrow, or other tissue.

Analysis population: Because there were no differences in chimerism results as a function of either the immunosuppression used or busulfan dose received, the results are being reported only for the total population.

Groups in this outcome

Experimental: GVHD Prophylaxis

Matched related donor (MRD) subjects receive Graft Vs Host Disease (GVHD )prophylaxis with Methotrexate alone Subjects also receive busulfan, fludarabine, and tacrolimus and may receive Alemtuzumab. Matched unrelated donor (MUD) or mismatched related donor (MMRD) subjects receive GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) + Methotrexate Subjects also receive busulfan, fludarabine, and tacrolimus.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Experimental: GVHD Prophylaxis54

Reported measurements

Whole blood chimerism-Any
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Experimental: GVHD Prophylaxis49Not reportedNot reportedNot reportedNot reported
Whole blood chimerism->=95% donor
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Experimental: GVHD Prophylaxis47Not reportedNot reportedNot reportedNot reported
T Cell chimerism-Any
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Experimental: GVHD Prophylaxis46Not reportedNot reportedNot reportedNot reported
T Cell chimerism>=95% donor
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Experimental: GVHD Prophylaxis30Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        49
    title
    Whole blood chimerism-Any
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        47
    title
    Whole blood chimerism->=95% donor
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        46
    title
    T Cell chimerism-Any
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        30
    title
    T Cell chimerism>=95% donor
denoms
  1. counts
    1. group Id
      OG000
      value
      54
    units
    Participants
description
Deoxyribonucleic acid (DNA) chimerism is a measure identifying the genetic profiles of the transplant recipient and of the donor and then evaluating the extent of mixture in the recipient's blood, bone marrow, or other tissue.
groups
  1. description
    Matched related donor (MRD) subjects receive Graft Vs Host Disease (GVHD )prophylaxis with Methotrexate alone Subjects also receive busulfan, fludarabine, and tacrolimus and may receive Alemtuzumab. Matched unrelated donor (MUD) or mismatched related donor (MMRD) subjects receive GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) + Methotrexate Subjects also receive busulfan, fludarabine, and tacrolimus.
    id
    OG000
    title
    Experimental: GVHD Prophylaxis
param Type
COUNT_OF_PARTICIPANTS
population Description
Because there were no differences in chimerism results as a function of either the immunosuppression used or busulfan dose received, the results are being reported only for the total population.
reporting Status
POSTED
time Frame
30 days post transplant
title
Incidence of DNA Chimerism in Patients Between One Month Post Transplant
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice